Across TCGA pan-cancer cohorts, MAFB Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MAFB data layer compared with 23 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher MAFB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAFB expression acts as an unfavorable survival marker.
BLCA, SKCM, and KIRC are the cancer types where MAFB Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.